low-tension glaucoma

(redirected from normal-tension glaucoma)

low-ten·sion glau·co·ma

optic nerve atrophy and excavation with typical field defects of glaucoma but without abnormal increase in intraocular pressure.

low-ten·sion glau·co·ma

(lōw-ten'shŭn glaw-kō'mă)
Optic nerve atrophy and excavation with typical field defects of glaucoma but without abnormal increase in intraocular pressure.
Synonym(s): normal-tension glaucoma.

low-tension glaucoma

A type of glaucoma in which intraocular pressures are normal (less than 22 mm Hg).
See also: glaucoma
References in periodicals archive ?
Other less common types of glaucoma include normal-tension glaucoma (NTG), pseudoexfoliation glaucoma, and pigmentary glaucoma (NEI, 2014b).
Research under way reveals that loss of vision in normal-tension glaucoma in particular is due to both intraocular pressure and low blood flow.
29) The effectiveness of significant IOP-lowering treatment has been established for NTG, with the Collaborative Normal-Tension Glaucoma Study Group (NTGS) reporting that lowering IOP by 30% from baseline can be effective in decreasing the rate of visual field loss in normal tension glaucoma.
Normal-tension glaucoma is a form of glaucoma where optic nerve damage continues despite relatively low intraocular pressures (as opposed to traditional glaucoma where the intraocular pressure is elevated).
found a high incidence of sleep apnea in subjects with normal-tension glaucoma (i.
Some people with normal eye pressure develop glaucoma, a disease known as low-tension or normal-tension glaucoma (NTG).
I have cataracts and am worried about the possibility of developing normal-tension glaucoma (NTG).
Chaudhary found that 30% of patients with normal-tension glaucoma also had sleep apnea (J.
In fact, Harvard researchers say that about half of all normal-tension glaucoma patients and one-third of all primary open-angle glaucoma patients suffer from obstructive sleep apnea.
12%, which was approved for marketing in Japan in 1994, is the world's first "Prostone" medicine for the treatment of glaucoma and ocular hypertension, and has been reported to have ion (K+ ion) channel opening activity and is able to not only lower the intraocular pressure, but also provide sustained optic nerve protection (in vitro) and improve ocular blood flow in patients with normal-tension glaucoma.
In fact, Harvard researchers say that about half of all normal-tension glaucoma patients and one third of all primary open-angle glaucoma patients suffer from obstructive sleep apnea.
Earlier this year, InSite Vision obtained the exclusive worldwide rights to the Optineurin gene and its mutations, which have been linked to primary open-angle glaucoma, including a subgroup known as normal-tension glaucoma.